Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma
Thurner, Lorenz; Hartmann, Sylvia; Fadle, Natalie; Regitz, Evi; Kemele, Maria; Kim, Yoo Jin; Bohle, Rainer Maria; Nimmesgern, Anna; von Müller, Lutz; Kempf, Volkhard A.J.; Weniger, Marc A.; Neumann, Frank; Schneider, Nadine; Vornanen, Martine; Sundström, Christer; de Leval, Laurence; Engert, Andreas; Eichenauer, Dennis A.; Küppers, Ralf; Preuss, Klaus Dieter; Hansmann, Martin Leo; Pfreundschuh, Michael (2020)
Thurner, Lorenz
Hartmann, Sylvia
Fadle, Natalie
Regitz, Evi
Kemele, Maria
Kim, Yoo Jin
Bohle, Rainer Maria
Nimmesgern, Anna
von Müller, Lutz
Kempf, Volkhard A.J.
Weniger, Marc A.
Neumann, Frank
Schneider, Nadine
Vornanen, Martine
Sundström, Christer
de Leval, Laurence
Engert, Andreas
Eichenauer, Dennis A.
Küppers, Ralf
Preuss, Klaus Dieter
Hansmann, Martin Leo
Pfreundschuh, Michael
2020
2465
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202101201521
https://urn.fi/URN:NBN:fi:tuni-202101201521
Kuvaus
Peer reviewed
Tiivistelmä
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma of B-cell origin with frequent expression of functional B-cell receptors (BCRs). Here we report that expression cloning followed by antigen screening identifies DNA-directed RNA polymerase beta’ (RpoC) from Moraxella catarrhalis as frequent antigen of BCRs of IgD+ LP cells. Patients show predominance of HLA-DRB1*04/07 and the IgVH genes encode extraordinarily long CDR3s. High-titer, light-chain-restricted anti-RpoC IgG1/κ-type serum-antibodies are additionally found in these patients. RpoC and MID/hag, a superantigen co-expressed by Moraxella catarrhalis that is known to activate IgD+ B cells by binding to the Fc domain of IgD, have additive activation effects on the BCR, the NF-κB pathway and the proliferation of IgD+ DEV cells expressing RpoC-specific BCRs. This suggests an additive antigenic and superantigenic stimulation of B cells with RpoC-specific IgD+ BCRs under conditions of a permissive MHC-II haplotype as a model of NLPHL lymphomagenesis, implying future treatment strategies.
Kokoelmat
- TUNICRIS-julkaisut [16983]